Explore post-immunotherapy options for advanced squamous NSCLC, weighing docetaxel±ramucirumab, patient concerns, and why new trials matter.

When immunotherapy stops working in squamous NSCLC, clinicians weigh docetaxel±ramucirumab, weekly dosing, and clinical trials.

In this segment, Dr. Christian Rolfo reviews emerging therapeutic approaches being investigated for patients with advanced squamous non-small cell lung cancer (NSCLC) following progression on immunotherapy.

In this segment, the panel discusses the potential role of genomic testing and biomarker identification in advanced squamous non-small cell lung cancer (NSCLC), particularly as new therapeutic approaches emerge following immunotherapy.

In this segment, the panel explains the biological rationale for combining CTLA-4 and PD-1 inhibition in advanced squamous non-small cell lung cancer (NSCLC).

In this segment, the panel discusses the toxicity profile of CTLA-4-directed therapies and how experience with immune-modulating treatments has influenced their use in advanced squamous non-small cell lung cancer (NSCLC).

In this segment, the panel discusses the importance of proactive monitoring and multidisciplinary management of immune-related toxicities in patients with advanced squamous non-small cell lung cancer (NSCLC).

In this segment, the panel discusses next-generation CTLA-4-directed therapies being engineered with the goal of improving selectivity and reducing the systemic toxicities associated with earlier CTLA-4 inhibitors in advanced squamous non-small cell lung cancer (NSCLC).

In this segment, the panel explores the rationale for selectively targeting CTLA-4 within the tumor microenvironment in advanced squamous non-small cell lung cancer (NSCLC), with particular attention to intratumoral regulatory T cells (Tregs) and the potential to improve antitumor activity while limiting systemic toxicity.

In this segment, the panel examines early clinical data for a next-generation CTLA-4-directed therapy in patients with advanced squamous non-small cell lung cancer (NSCLC) whose disease has progressed following PD-L1 inhibitor and chemotherapy treatment.

In this segment, the panel reviews additional clinical data from the initial stage of the trial evaluating next-generation CTLA-4-directed therapy in advanced squamous non-small cell lung cancer (NSCLC).

In this segment, the panel discusses the emerging safety profile of next-generation CTLA-4-directed therapy in advanced squamous non-small cell lung cancer (NSCLC) and how toxicity findings should be interpreted alongside efficacy data.

In this segment, the panel discusses treatment considerations for patients with advanced squamous non-small cell lung cancer (NSCLC) who have progressed following immunotherapy and platinum-based chemotherapy but do not want additional chemotherapy.

In this segment, the panel discusses how emerging therapies may be incorporated into treatment for patients with advanced squamous non-small cell lung cancer (NSCLC) who have experienced challenges with prior immune checkpoint inhibitors.